Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y 12 -inhibition after ticagrelor intake.
Autor: | Hobl EL; Departments of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria., Jilma B, Derhaschnig U, Schoergenhofer C, Schwameis M, Jilma-Stohlawetz P |
---|---|
Jazyk: | angličtina |
Zdroj: | Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2013 Jul 29. Date of Electronic Publication: 2013 Jul 29. |
DOI: | 10.1002/cytob.21119 |
Abstrakt: | Background: Ticagrelor is a P2Y Methods: We hypothesized that the conventional and new methods may be comparable when ticagrelor is used. We pair-wise compared the platelet reactivity index (PRI) between assays in a prospective clinical trial. Six healthy volunteers received a single 180 mg loading dose of ticagrelor. Results: PRI-values of the two methods correlated well (r=0.97, p<0.001). Ticagrelor rapidly decreased PRI values on average after 50 minutes, but nadir levels 2-6 hours after ticagrelor intake were 15% higher when PRI% was measured with the flow cytometric method. Bland-Altman analysis showed that the flow cytometric assay measured markedly higher PRI levels than the new ELISA-based technique (mean difference 13%). Conclusions: The new ELISA-based VASP assay offers an alternative to the currently used flow cytometric method, but measures lower PRI levels, particularly when PRI falls below 20% after ticagrelor intake. © 2013 Clinical Cytometry Society. (Copyright © 2013 Clinical Cytometry Society.) |
Databáze: | MEDLINE |
Externí odkaz: |